Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.04 -0.10 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,928,796
Open 58.18
Bid (Size) 57.86 (1)
Ask (Size) 59.50 (1)
Prev. Close 58.14
Today's Range 57.87 - 58.46
52wk Range 57.61 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 3.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
3 Dividend Stocks to Buy and Hold Until Retirement
Together, these stocks can also help diversify your portfolio by giving you exposure to different industries. 
Via The Motley Fool

Performance

YTD
-19.68%
-19.68%
1 Month
-6.96%
-6.96%
3 Month
-9.24%
-9.24%
6 Month
-16.26%
-16.26%
1 Year
-19.06%
-19.06%

More News

Read More
Bristol-Myers Squibb Unusual Options Activity For September 27
Via Benzinga
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
From Bristol Myers Squibb
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
2 Undervalued Dividend Stocks to Buy Now
Via The Motley Fool
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
Via FinancialNewsMedia
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
Via InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Via Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
Via Benzinga
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Via InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
Via Benzinga
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
From Bristol Myers Squibb
Via Business Wire
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
Via InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Via Benzinga
Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
Via Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
Via Benzinga
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.